Image

Evaluation of a Transfusion Therapy Using Whole Blood in the Management of Coagulopathy in Patients With Acute Traumatic Hemorrhage

Recruiting
18 years of age
Both
Phase 3

Powered by AI

Overview

The prognosis of traumatized hemorrhages is correlated with the nature of transfusion therapy: a 50% reduction in mortality for an early and massive supply of plasma, and 20% for an early and massive supply of platelets. However, this strategy encounters logistical difficulties, particularly in a context of collective emergency (attacks). The use of whole blood, widely documented by the Armed Forces, improves the availability of plasma and platelets, and simplifies handling by the various actors in the chain.

T-STORHM is a randomized, controlled, parallel clinical trial.This study tests non-inferiority of whole blood transfusion therapy in the management of coagulopathy in patients with acute traumatic hemorrhage.

Description

In recent years, terrorist attacks have confronted the investigator's healthcare system with a massive influx of victims of war weapon injuries. This new fact makes the efficiency of transfusion therapy crucial: hemorrhage is the leading cause of death from weapons of war, and the high number of victims of each attack changes the logistical approach.

The logistical problems with transfusion therapy, including red blood cell (PRBCs), plasma and platelet concentrates, are the speed of delivery and availability. Using whole blood is a pragmatic solution to overcome these problems. This solution has been used for many years by the French Army to ensure platelet transfusion in traumatic hemorrhages

The hypothesis of the T-STORHM study is that the use of whole blood is a solution in a context of civil trauma not effective less than component therapy (PRBCs, plasma and platelet concentrates) in the management of coagulopathy in patients admitted to hospital for traumatic hemorrhage.

Eligibility

Inclusion Criteria:

        Severe trauma patients requiring the initiation of a massive transfusion protocol
        determined on
          1. At least two Red flag score factors (according to pre-hospital data) :
               -  Suspected pelvic fracture
               -  Shock index (FC / PAS)> = 1
               -  Microdose hemoglobin <13g
               -  Average blood pressure <70 mmHg
               -  Need for prehospital tracheal intubation
          2. AND at least two criteria of the Assessment of Blood Consumption (ABC) score
             established at the patient's arrival:
               -  Penetrating trauma
               -  Focused Abdominal Sonography for Trauma (FAST) echo positive
               -  Blood pressure <90 mmHg
               -  Respiratory rate >120 bpm
          3. AND/OR on the prediction of the practitioner (clinical diagnosis) in charge of the
             treatment of the injured person of the need to transfuse at least 4 PRBCs within 6
             hours after the admission of the trauma patient
        Exclusion Criteria:
          -  Non-traumatic hemorrhage
          -  Patients transfused with more than two PRBCs before the initiation of the massive
             transfusion protocol.
          -  Anti-coagulation treatment
          -  Pregnancy
          -  Age < 18 years
          -  Patient refusing administration of blood products
          -  Patient transferred from another hospital
          -  Patient nor transported by a physician-staffed prehospital emergency medical system
          -  Burn patient (≥30% of body surface).
          -  Patient under specific known transfusion protocol (for example : allo immunization...)

Study details

Trauma, Acute Hemorrhage, Coagulopathy

NCT04431999

Direction Centrale du Service de Santé des Armées

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.